The ecotropic viral integration site-1 (EVI-1) is a nuclear transcription factor and has an essential function in the proliferation/maintenance of haematopoietic stem cells. Aberrant expression of EVI-1 has been frequently found in myeloid leukaemia as well as in several solid tumours, and is associated with a poor patient survival. It was recently shown that EVI-1 associates with two different histone methyltransferases (HMTs), SUV39H1 and G9a. However, the functional roles of these HMTs in EVI-1-mediated leukemogenesis remain unclear. In this study, we showed that EVI-1 physically interacts with SUV39H1 and G9a, but not with Set9. Immunofluorescence analysis revealed that EVI-1 colocalizes with these HMTs in nuclei. We also found that the catalytically inactive form of SUV39H1 abrogates the transcriptional repression mediated by EVI-1, suggesting that SUV39H1 is actively involved in EVI-1-mediated transcriptional repression. Furthermore, RNAi-based knockdown of SUV39H1 or G9a in Evi-1-expressing progenitors significantly reduced their colony-forming activity. In contrast, knockdown of these HMTs did not impair bone marrow immortalization by E2A/HLF. These results indicate that EVI-1 forms higher-order complexes with HMTs, and this association has a role in the transcription repression and bone marrow immortalization. Targeting these HMTs may be of therapeutic benefit in the treatment for EVI-1-related haematological malignancies.
Introduction
The ecotropic viral integration site-1 (Evi-1) gene was first identified as a common locus of retroviral integration in murine leukaemia models. 1, 2 In humans, EVI-1 is located on chromosome 3q26, and rearrangements on chromosome 3q26 often activate EVI-1 expression in myelodysplastic syndrome (MDS) and acute myeloid leukaemia. Importantly, high EVI-1 expression is an independent negative prognostic indicator of survival in acute myeloid leukaemia, irrespective of the presence of 3q26 rearrangements.
3,4 EVI-1 possesses diverse functions as an oncoprotein. EVI-1 antagonizes growth-inhibitory effects of transforming growth factor-b (TGF-b); 5 protects cells from stress-induced cell death by inhibiting c-Jun N-terminal kinase; 6 increases the expression of endogenous c-Jun and c-fos, resulting in the activation of AP-1. 7 Mouse models in which Evi-1 is retrovirally expressed in haematopoietic cells showed that activation of Evi-1 leads to myeloid dysplasia, 8 whereas the development of full-blown leukaemia requires additional genetic events. 9, 10 Furthermore, recent gene targeting studies in mice revealed that Evi-1 has an essential function in the proliferation/maintenance of haematopoietic stem cells. 11, 12 EVI-1 contains DNA-binding zinc finger motifs and belongs to the positive regulatory (PR) domain family of transcription factors, which are characterized by the presence of multiple zinc fingers and a PR domain at the N-terminus. 13 The PR domain is a subclass of the evolutionarily conserved SET domain, which has been linked to chromatin-mediated gene regulation and histone methylation. There are two major alternative forms generated from EVI-1 gene, EVI-1 (PR-absent form) and MDS1-EVI-1 (PR-containing form, also called EVI-1c) (Figure 1a ). Although related, functional differences between EVI-1 and MDS1-EVI-1 have been documented. 14, 15 In addition to its DNA-binding activity, EVI-1 has the potential to recruit diverse proteins, such as Smad3, HDACs and CtBP, 5, [16] [17] [18] thus generating complexes for transcriptional regulation.
Methylation of specific histone residues has an essential regulatory function in gene transcription. Specifically, methylation of histoneH3 lysine 9 (H3K9) is associated with gene silencing. After the initial identification of SUV39H1 as a H3K9-specific histone methyltransferase (HMT), 19 at least three other HMTs, G9a, GLP and SETDB1, have been recognized as HMTs for H3K9 in mammals. 20 Very recently, two independent groups reported that EVI-1 physically interacts with the H3K9 HMTs, SUV39H1 and G9a. 21, 22 However, functional roles of these HMTs in EVI-1-mediated leukemogenesis remain unclear.
In this study, we showed that EVI-1 interacts and colocalizes with SUV39H1 and G9a. Remarkably, RNAi-based knockdown of these HMTs in Evi-1-expressing progenitors significantly reduced their colony-forming activity, suggesting that these HMTs could be therapeutic targets in poor prognosis leukaemia with aberrant EVI-1 expression.
Materials and methods

DNA constructs
The plasmid pME18S-Flag-EVI-1, pME18S-Flag-MDS1-EVI-1, pMXs-neo-E2A/HLF (a gift from T Inaba) have been described earlier. 12, 14 The pCMV-Myc-SUV39H1 and pEGFPC1-G9a were gifts from M Tachibana and Y Shinkai. SUV39H1-H324K was created by PCR mutagenesis to change amino acid 324 from histidine to lysine. The pCDNA3.1HA-G9a and pcDNA3.1HA-G9a-NH903/904LE were gifts from K Wright. The pCDNA3.1-Flag-Set9 was a gift from D Reinberg. Mouse Evi-1 cDNA was obtained using the mRNA prepared from para-aortic splanchnopleura (P-Sp) region of the embryo, and inserted into the pGCDNsam-eGFP retroviral vector (a gift from H Nakauchi and M Onodera).
HMT assay
Flag-EVI-1, Myc-SUV39HA or HA-G9a was immunoprecipitated with anti-Flag, anti-Myc and anti-HA antibodies, respectively. The immunoprecipitates were incubated for 1 h at 37 1C in 50 ml of MAB buffer (50 mM Tris, pH 8.5, 20 mM KCl, 10 mM MgCl2, 10 mM b-mercaptoethanol, 250 mM sucrose) containing 2 mg of histone 3 (Roche, Indianapolis, IN, USA) as the substrate and S-adenosyl-[methyl-14C]-l-methionine as the methyl donor. Reactions were stopped by boiling the samples in sodium dodecyl sulphate loading buffer, and then the proteins were separated by Roles of HMTs in EVI-1-mediated leukemogenesis S Goyama et al 15% sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Gels were dried and quantification of methyl-
14
C was performed using a BAS-2000 imaging analyzer (Fuji Film).
Immunoprecipitation and western blotting
The 293T cells were transfected by the calcium phosphate method. The cells were cultured 48 h after transfection and were lysed in the TNE buffer.
14 For immunoprecipitation, cell lysates were incubated with the anti-Flag M2 monoclonal antibody (F3165, Sigma, St Louis, MO, USA) for 3 h at 4 1C. Then, the samples were incubated with protein-G-Sepharose (Amersham Pharmacia Biotech, Piscataway, NJ, USA) for 1 h at 4 1C. The precipitates were washed five times with the TNE buffer, subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis, and analysed by western blotting. Western blotting was performed with anti-Flag M2-Peroxidase (A8592, Sigma), anti-Myc (2276, Cell Signaling Technology, Beverly, MA, USA), anti-HA-Peroxidase (12CA5, Roche), anti-GFP antibody (G1544, Sigma), anti-EVI-1 (C50E12, Cell Signaling Technology), anti-SUV39H1 (MG44, upstate) or anti-G9a antibody (C6H3, Cell Signaling Technology). Proteins were visualized by the enhanced chemiluminescence system (Amersham Pharmacia Biotech).
Immunofluorescence microscopy
For colocalization studies, COS7 cells were transfected with Myc-SUV39H1 or GFP-G9a together with Flag-EVI-1 using the FuGENE transfection reagent (Roche). After 48 h, cells were fixed in 3.7% formaldehyde and permealized with 0.1% Triton X-100. Samples were blocked with 1% bovine serum albumin for 40 min, incubated with mouse anti-Myc-FITC (F2047, Sigma) or rabbit anti-Flag antibody (F7425, Sigma) for 2 h, washed, and then incubated with the Alexa Fluor 555 conjugated goat antirabbit antibody. For evaluation of endogenous H3K9 methylation status, MEF cells were incubated with rabbit anti-dimethyl H3K9 (29698, Upstate) or rabbit anti-trimethyl H3K9 antibody (31855, Upstate), followed by labelling with Alexa Fluor 488 conjugated anti-rabbit antibody. Nuclear staining was performed using TOPRO3 (Invitrogen, Carlsbad, CA, USA). Cells were analysed by the confocal laser scanning microscopy (Leica TCS SL).
Luciferase reporter assay
For analysis of luciferase activities, 293T cells were seeded in 12-well culture plates at a density of 1 Â 10 5 per well. At 12 h after seeding, the cells were transfected with 500 ng of p3TP-Lux, 100 ng of pME-EVI-1, and increasing amounts (100 or 200 ng) of either pcDNA3-SUV39H1, pcDNA3-SUV39H1-H324K, pcDNA3-G9a or pcDNA3-G9a-NH903/904LE using Lipofectamin 2000 (Invitrogen). The cells were harvested 48 h after transfection and assayed for the luciferase activity by means of the luciferase assay system (Promega, Madison, WI, USA) and a luminometer (Lumat, LB 9700, Berthold, Bad Wildbad, Germany). Transfection efficiency was evaluated by cotransfecting 10 ng of a reporter CMV-bgalactosidase plasmid. 
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Retrovirus transduction and colony-replating assay
Plat-E packaging cells 23 were transiently transfected with 3 mg of retrovirus vectors, mixed with 9 ml of FuGENE 6 (Roche) for retrovirus production. Colony-replating assay was performed as described earlier. 24 Colony-forming cells from the third to fifth round of plating were subsequently infected with retrovirus encoding either Suv39H1-small hairpin RNA (shRNA), G9a-shRNA or control-shRNA, and the cells were replated at 1 Â 10 5 per plate in M3434 in the presence of 1 mg/ml puromycin. Puromicin-resistant colonies were then replated at 5 Â 10 3 per plate.
RNA interference
We designed retrovirus vectors (RNAi-Ready pSIREN-RetroQ Vector, Clontech, Palo Alto, CA, USA) encoding an shRNA directed against murine Suv39h1 or G9a. As a control, we used an shRNA vector without hairpin oligonucleotides. 
Statistical analysis
Statistical significance of differences between parameters was assessed using Welch's t-test.
Results
EVI-1 associates with SUV39H1 and G9a in mammalian cells
As PR domain is homologous to the catalytic SET domains of HMTs, we initially assessed whether MDS1-EVI-1 (PR-containing form) is able to transfer methyl groups onto histones. We purified recombinant full-length EVI-1 and MDS1-EVI-1 from 293T cell extracts by immunopurification and analysed them by an in vitro HMT assay with histone H3 as a substrate. However, the immunoprecipitated EVI-1 protein (both EVI-1 and MDS1-EVI-1) had no methyltransferase activity (Figure 1b) , indicating that MDS1-EVI-1 itself is not a HMT. We then investigated whether EVI-1 can associate with H3K9-specific HMTs, SUV39H1 and G9a in mammalian cells. We introduced Flagtagged EVI-1 or MDS1-EVI-1 in the absence or presence of Myc-SUV39H1 into 293T cells. Cell lysates were subjected to immunoprecipitation with anti-Flag, followed by immunoblotting with anti-Myc. We observed that Myc-SUV39H1 was coprecipitated with both Flag-EVI-1 and Flag-MDS1-EVI-1 ( Figure 1c ). Using the same assay, we also found that GFPG9a could be detected in immunoprecipitates of both Flag-EVI-1 and Flag-MDS1-EVI-1 (Figure 1d ). In contrast, Flag-SET9 did not show any interaction with HA-EVI-1 (Figure 1e ). Thus, both isoforms of EVI-1 are able to form a complex with two H3K9 methyltransferases, SUV39H1 and G9a. We next mapped the region of EVI-1 that is necessary for interaction with the HMTs using EVI-1 deletion mutants that lack various functional domains (Figure 2a) . 25 The first zinc 
Roles of HMTs in EVI-1-mediated leukemogenesis S Goyama et al
finger domain (ZF1) is a DNA-binding domain and is essential for interaction with several proteins, including Smad3 and c-Jun N-terminal kinase. 5, 6 The second zinc finger domain (ZF2) is another DNA-binding domain and is essential for AP-1 activation. 7 The repression domain is required for the efficient repression of TGF-b signalling. 5 The region containing CtBPbinding-motif-like sequences is responsible for the interaction with CtBP1. 16 In addition, EVI-1 contains a highly acidic domain at the C-terminus, which is required for EVI-1-mediated P-Sp haematopoiesis. 26 In contrast to the earlier reports, which showed that EVI-1 interacts with SUV39H1 through ZF1, 21 ,22 all of these deletion mutants associate with both SUV39H1 and G9a almost as efficiently as full-length EVI-1 (Figure 2b and c) . These results indicate that the interactions between EVI-1 and HMTs are mediated through a relatively wide stretch of multiple regions, at least in 293T cells.
EVI-1 colocalizes with SUV39H1 and G9a in the nucleus
Next, we examined whether EVI-1 and the HMTs could colocalize in cells using immunofluorescence analysis with COS7 cells. Consistent with earlier reports, 27 EVI-1 shows a nuclear diffused localization pattern in the majority of cells, and sometimes shows speckled nuclear distribution (Figure 3a and b, left). When both Flag-tagged EVI-1 and Myc-tagged SUV39H1 were cotransfected into COS7 cells, EVI-1 and SUV39H1 formed speckles that partially overlap (yellow colour) in nuclei, confirming the colocalization between two proteins in vivo (Figure 3a, right) . The possibility of cross-talk between the channels or cross-reactivity of the antibodies was ruled out (Supplementary Figure 1) . The same assay also revealed nearly complete colocalization of EVI-1 and G9a in cells transfected with both constructs (Figure 3b, right) . Thus, EVI-1 and the HMTs (SUV39H1 and G9a) colocalize within the nucleus in mammalian cells.
EVI-1 is not essential for the global methylation of H3K9
It has been shown that SUV39H1 is required for H3K9 trimethylation (H3K9-3Me) and G9a promotes H3K9 dimethylation (H3K9-2Me). 28 Therefore, we then examined the effect of Evi-1 deletion on the overall levels of di-and tri-methylation of H3K9 in wild-type and Evi-1 À/À MEF cells. The absence of Evi-1 protein in Evi-1 À/À MEF cells was confirmed by western blotting (Figure 4a ). As shown in Figure 4b , H3K9-2Me and 3Me were broadly detected in nuclei of MEF cells, and Evi-1 À/À cells showed no remarkable change on overall methylation levels.
Thus, Evi-1 deficiency does not cause significant reduction of H3K9 methylation level in MEF cells.
Transcriptional repression by EVI-1 requires catalytically active SUV39H1
We next investigated whether SUV39H1 and G9a are actively involved in EVI-1-mediated transcriptional repression. We transfected 293T cells with the reporter plasmid p3TP-Lux, a synthetic TGF-b-responsive reporter that contains the promoter region of the plasminogen activator inhibitor 1 (PAI-1). As shown earlier, cotransfection of EVI-1 resulted in repression of the reporter activity. Interestingly, increasing amounts of SUV39H1-H324K, a construct carrying an inactivating point mutation within the HMT domain of SUV39H1, completely abrogated the transcriptional repression mediated by EVI-1 ( Figure 5 ). As H324K is still able to associate with EVI-1 in immunoprecipitation studies (Figure 2b) , it is thought to act as a dominant-negative mutant by competing with endogenous SUV39H1. In contrast, both G9a and G9a-NH903/904LE, a construct carrying inactivating mutations within the HMT domain of G9a, did not affect the reporter activity ( Figure 5 ). 
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These results suggest that SUV39H1 is more important for EVI-1-mediated transcriptional repression in this context.
Both SUV39H1 and G9a are required for efficient propagation of Evi-1-expressing cells
We then evaluated a role for HMTs in Evi-1-induced leukemogenesis. Bone marrow cells from 5-fluorouracil-treated mice were transduced with Evi-1, and were subjected to colonyreplating assay (Figure 6a ). Consistent with earlier reports, 29 primary bone marrow progenitors transduced with Evi-1, but not empty vector, formed colonies in methylcellulose that can be replated through at least seven rounds of culture (data not shown). Wright-Giemsa-stained cytospin preparations of the cells constituting these Evi-1-transduced colonies showed blastic morphology with myeloid dysplasia (Figure 6b ). After establishment of sustained clonogenic activity after more than three rounds of replating, the cells were transduced with Suv39h1-shRNA, G9a-shRNA or control-shRNA. We designed two independent shRNAs targeting murine Suv39H1 or G9a, and confirmed reduced expression of these HMTs by quantitative PCR in Evi-1-transduced cells and by western blotting in NIH3T3 cells (Figure 6c; Supplementary Figure 2) . Although the colony-forming activity vary among different cultures (Supplementary Table 2 ), knockdown of Suv39h1 or G9a in Evi-1-transduced progenitors showed a clear tendency to reduce Table 2 ). In addition, the HMT-knockdown cells exhibited a tendency to differentiate towards a granulocytic lineage in some experiments (Supplementary Figure 3B) . We then assessed a role for the HMTs in bone marrow immortalization by E2A/HLF, a chimeric gene generated in t (17;19) that is also known to immortalize murine bone marrow cells. 30 We used E2A/HLF as a control because the contribution of Evi-1 to colony-forming ability of E2A/HLF-transduced cells is relatively small. 12 Despite the efficient downregulation of Suv39h1 and G9a (Figure 6e) , the HMT-knockdown cells showed equivalent colony-forming activity to that of control E2A/HLF-transduced cells (Figure 6f; Supplementary Table 2 ). These results indicate that both Suv39h1 and G9a are specifically required for Evi-1-mediated bone marrow immortalization.
Discussion
Understanding mechanisms underlying EVI-1-mediated leukemogenesis is essential to develop new therapy for leukaemias with high EVI-1 expression, which are often predictive of poor clinical outcome. Very recently, it was shown that EVI-1 physically interacts with H3K9 HMTs, 21, 22 suggesting that EVI-1 regulates transcription by recruiting these HMTs. Here, we extended these analyses and found that the HMTs are important for colony-replating ability of Evi-1.
The PR domain is a subclass of SET domains most closely related to the known HMTs. However, we found that MDS1-EVI-1 (PR-containing form) showed no HMT activity. It was shown earlier that PRDI-BF1 (Blimp-1), another member of PR gene family, exhibits HMT activity by recruiting G9a regardless of its PR domain. 31 Similarly, as we and others have shown, EVI-1 interacts with two HMTs, SUV39H1 and G9a. Therefore, it is likely that EVI-1 is involved in histone modification by recruiting other proteins, not through its PR domain.
Earlier reports showed that wild-type SUV39H1 enhances the repressive potential of Gal4-EVI-1 on the activity of a promotercontaining GAL4 sites, whereas the effect is not observed when the catalytically inactive mutant (SUV39H1-H324K) was used. 21, 22 In contrast to these reports, we found that SUV39H1-H324K acts in a dominant-negative manner to abrogate EVI-1-mediated repression of p3TP-Lux reporter activity, whereas wild-type SUV39H1 has little effect on the repression by EVI-1. This discrepancy is probably because of the different cell types and/or promoters used for the assays. Thus, SUV39H1 is actively involved in EVI-1-mediated transcription but its effects are strictly dependent on the context. Although we did not observe significant changes in the EVI-1-mediated p3TP reporter repression by G9a or its catalytically inactive mutant (G9a-NH903/904LE), the possible requirement of G9a for EVI-1-mediated transcriptional regulation should be assessed in different experimental settings. Furthermore, because genes downregulated by EVI-1 have not been identified thus far, identification of repressive target genes of EVI-1 is an important future challenge.
Downregulation of Suv39h1 or G9a in Evi-1-transduced cells significantly inhibited their colony-forming activity. It may indicate the importance of these HMTs for generation of leukaemia-initiating cells by Evi-1. Alternatively, these HMTs may support efficient propagation of Evi-1-expressing leukaemic cells. To clarify a precise role of Evi-1/HMT complex in leukemogenesis, further in vivo studies are warranted. In contrast to Evi-1-induced immortalization, both Suv39h1 and G9a are dispensable for bone marrow immortalization by E2A/HLF. Although we have shown that complete loss of Evi-1 slightly reduced colony-forming ability of E2A/HLF, the effect of Evi-1 deletion in E2A/HLF-immortalized cells is relatively small than that in MLL-immortalized cells. 12 It therefore seems likely that the Evi-1/HMT interaction is not a major mediator for oncogenic activity of E2A/HLF.
Recently, several inhibitors targeting SUV39H1 and G9a have been identified. 32, 33 Furthermore, we have shown that a HDAC inhibitor, trichostatin A, alleviates Evi-1-mediated repression of TGF-b signalling. 16 Therefore, combined epigenetic therapy with the HMT and the HDAC inhibitors may exert synergistic activity against EVI-1-expressing leukaemic cells, and it also needs to be evaluated in the future.
In summary, we showed that EVI-1 interacts and colocalizes with SUV39H1 and G9a. The interaction contributes, at least in part, to the transcriptional repression and bone marrow immortalization by EVI-1. Although further studies are required to address the mechanistic links between histone methylation and EVI-1-mediated leukemogenesis, our results indicate that targeting these HMTs could be of therapeutic benefit in the treatment for EVI-1-related haematological malignancies.
